Clinical Trials
12 trialsNCT07504588 2026-06-03
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07178730 2026-05-06
ADAPT-TN-IV
West German Study Group
Phase 3 Not yet recruiting
NCT07438600 2026-03-27
TianjinCIH
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07393555 2026-02-06
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Not yet recruiting
NCT07367178 2026-01-28
SATROPIN
MedSIR
Phase 2 Not yet recruiting
NCT07368543 2026-01-28
STORM
Fudan University
Phase 2 Not yet recruiting
NCT07299409 2025-12-23
First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
British Columbia Cancer Agency
Phase 2 Not yet recruiting
NCT07163481 2025-09-16
SoGreat
Hunan Cancer Hospital
Phase 1 Not yet recruiting
NCT07040644 2025-09-08
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07151586 2025-09-03
ALTER
UNICANCER
Phase 2 Not yet recruiting
NCT06528483 2024-07-30
preSAVE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Not yet recruiting
NCT06462079 2024-06-17
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
Guangzhou Medical University
Phase 2 Not yet recruiting